Vivo Bio Tech Ltd. () - Stock Overview & Analysis

Search your stocks

Profile

vivo-bio-techVivo Bio Tech Ltd.

₹38.53-1.21%

Market Cap

₹79.62 Cr

Stock P/E

9.86

ROCE

9.97%

ROE

4.79%

Book Value

₹36.29

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Public

Others

Financials

YoY Net Sales

EPS Growth

Operating Margin

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Laggard

Vivo Bio Tech Ltd. is significantly lagging behind its peers in terms of growth, profitability, and efficiency metrics. With a negative revenue growth rate and lower return ratios, it presents a challenging outlook compared to stronger competitors in the pharmaceuticals sector.

Key Points

• Vivo Bio Tech Ltd. has negative revenue growth and EPS decline over the past three years.
• High debt-to-equity ratio (1.35) indicates potential financial risk.
• Sun Pharmaceutical Industries and Cipla Ltd. stand out as top performers in profitability metrics.

Top Performers

Cipla Ltd.

Strong revenue growth (13.28% YoY) and high ROE (16.63%) with low debt (0.0093).

Sun Pharmaceutical Industries Ltd.

Solid revenue growth (8.42% YoY), high ROE (16.13%), and almost negligible debt (0.0447).

Dr. Reddy's Laboratories Ltd.

Impressive growth in EPS (68.07) and high ROE (21.76%) alongside low valuation metrics.